Rheumatology Advance Access originally published online on February 3, 2005
Rheumatology 2005 44(3):390-397; doi:10.1093/rheumatology/keh514
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology Vol. 44 No. 3 © British Society for Rheumatology 2005; all rights reserved
GUIDELINES |
Guideline for anti-TNF-
therapy in psoriatic arthritis
Royal National Hospital for Rheumatic Diseases, Bath, 1 Board of Trustees and Management Committee, Psoriatic Arthropathy Alliance, 2 University of Manchester and Salford Royal Hospitals NHS Trust, Manchester, 3 University of Leeds, Leeds, 4 Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, 5 RCN Rheumatology Steering Committee, and 6 East Cheshire NHS Trust and ARC Epidemiology Unit, University of Manchester, Manchester, UK.
Correspondence to: Dr. Neil McHugh, Royal National Hospital for Rheumatic Diseases, Upper Borough Wells, Bath, BA1 IRL. E-mail: Neil.McHugh@rnhrd.tr.swest.nhs.uk
| The first 150 words of the full text of this article appear below. |
Scope and purpose
Background
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy with a prevalence between 0.1 and 1% and an equal sex distribution [1]. Psoriasis affects 1–3% of the population, with approximately a third of patients developing PsA [2]. The course of PsA is variable and unpredictable ranging from a mild non-destructive disease to a severe debilitating erosive arthropathy. Erosive and deforming arthritis occurs in 40–60% of PsA patients (followed at hospital clinics), and is progressive from within the first year of diagnosis [3, 4].
The classification of PsA is an area of ongoing international discussion. The five subgroups proposed by Moll and Wright [5] are still frequently used, although considerable overlap between these groups is now recognized. For the purpose of these guidelines we have differentiated between peripheral joint disease in PsA and axial disease alone. Psoriatic spondylitis is similar to ankylosing spondylitis
Need for guideline
Cost implications
Remit
Objectives
Target audience
Stakeholder involvement
Rigour of development
Literature review
Level of evidence
Updating
Guidelines for anti-TNF-
therapy in adults with psoriatic arthritis
Treatment algorithm for psoriatic arthritis (Fig. 1)
Standard therapy
Failure to respond to therapy
Licensed anti-TNF- therapy
Exclusion criteria
Clinical efficacy
Response to therapy
Withdrawal of therapy
Assessment
Monitoring and toxicity
Conflict of interest
Supplementary data
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M J Harrison, W G Dixon, K D Watson, Y King, R Groves, K L Hyrich, D P M Symmons, and the British Society for Rheumatology Biologics, and on behalf of the BSRBR Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor {alpha} therapy: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis, February 1, 2009; 68(2): 209 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L B S Gelinck, A E van der Bijl, W E P Beyer, L G Visser, T W J Huizinga, R A van Hogezand, G F Rimmelzwaan, and F P Kroon The effect of anti-tumour necrosis factor {alpha} treatment on the antibody response to influenza vaccination Ann Rheum Dis, May 1, 2008; 67(5): 713 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L C Coates, L S Cawkwell, N W F Ng, A N Bennett, D J Bryer, A D Fraser, P Emery, and H Marzo-Ortega Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience Ann Rheum Dis, May 1, 2008; 67(5): 717 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bravo Vergel, N. S. Hawkins, K. Claxton, C. Asseburg, S. Palmer, N. Woolacott, I. N. Bruce, and M. J. Sculpher The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis Rheumatology, November 1, 2007; 46(11): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Smith, K. Gadsby, S. Butt, D. Carruthers, A. Deeming, J. Ledingham, M. Fletcher, D. Mulherin, S. Roskell, L. Kay, et al. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres Rheumatology, October 1, 2007; 46(10): 1557 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Pariser, J. Bagel, J. M. Gelfand, N. J. Korman, C. T. Ritchlin, B. E. Strober, A. S. Van Voorhees, M. Young, S. Rittenberg, M. G. Lebwohl, et al. National Psoriasis Foundation Clinical Consensus on Disease Severity Arch Dermatol, February 1, 2007; 143(2): 239 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Kay, I. D. Griffiths, and for the BSR Biologics Register Management committe UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register Rheumatology, November 1, 2006; 45(11): 1376 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Luqmani, S. Hennell, C. Estrach, F. Birrell, A. Bosworth, G. Davenport, C. Fokke, N. Goodson, P. Jeffreson, E. Lamb, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first two years) Rheumatology, September 1, 2006; 45(9): 1167 - 1169. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Bansback, R. Ara, N. Barkham, A. Brennan, A. D. Fraser, P. Conway, A. Reynolds, and P. Emery Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis Rheumatology, August 1, 2006; 45(8): 1029 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Keat, N. Barkham, A. Bhalla, K. Gaffney, H. Marzo-Ortega, S. Paul, F. Rogers, M. Somerville, R. Sturrock, P. Wordsworth, et al. BSR guidelines for prescribing TNF-{alpha} blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology Rheumatology, July 1, 2005; 44(7): 939 - 947. [Full Text] [PDF]
|
|